6-(2-bromoethyl)benzothiazolone | 118306-80-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 6-(2-bromoethyl)benzothiazolone
• 英文别名: 6-(2-bromoethyl)benzothiazolinone；6-(2-bromoethyl)-3H-1,3-benzothiazol-2-one
• CAS: 118306-80-2
• 化学式: C₉H₈BrNOS
• 分子量: 258.139
• InChiKey: NCFBEYIGHKASMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(2-bromoethyl)benzothiazolone 在 potassium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 3-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-6-{2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-3H-benzothiazol-2-one
  参考文献：
  名称：

  5-HT1A and 5-HT2A ligands with anxiolytic and antipanic-like properties

  摘要：

  A series of new benzothiazolin-2-one, benzoxazolin-2-one and benzoxazin-3-one derivatives were synthesized and their binding profile at 5-HT1A, 5-HT2A, 5-HT2C as well as D-2 and alpha(1) receptors was determined. All studied compounds displayed high to moderate affinity for both 5-HT1A and 5-HT2A receptor subtypes. Among these, one compound (29) emerged since it exhibited potent antagonist activities at 5-HT1A, 5-HT2A, D-2 and alpha(1) central receptors and showed anxiolytic and antipanic-like effects in mice. 29 is currently undergoing preclinical evaluation. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10023-3
• 作为产物：
  描述：

  2-羟基苯并噻唑 在 三乙基硅烷 、 PPA 、 Polyphosphoric acid (PPA) 、 三氟乙酸 作用下， 反应 42.83h， 生成 6-(2-bromoethyl)benzothiazolone
  参考文献：
  名称：

  1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents

  摘要：

  The design and synthesis of a series of potential atypical antipsychotic agents based on the structure of 1-naphthylpiperazine are described. The incorporation of dopamine antagonist activity into the parent structure was achieved with heterocyclic surrogates for the catechol moiety of dopamine. Compound 4b from this series showed a biochemical profile that translated to behavioral activity in the rat predictive of an antipsychotic agent with a low propensity to cause extrapyramidal side effects in man.

  DOI：

  10.1021/jm00110a016

文献信息

• Method of treating tourette's syndrome and obsessive compulsive disorder
  申请人：Pfizer Inc.

  公开号：US06127373A1

  公开（公告）日：2000-10-03

  A method for treating Tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.

  在哺乳动物，包括人类中，治疗抽动症、强迫症、慢性运动或发声抽动障碍的方法，包括向该哺乳动物施用公式##STR1##中的化合物或其药用可接受的酸盐的有效量，其中n、X、Y和Ar如上所定义。
• Aryl piperazinyl-(C.sub.2 or C.sub.4) alkylene heterocyclic compounds
  申请人：Pfizer Inc.

  公开号：US04831031A1

  公开（公告）日：1989-05-16

  Arylpiperazinyl-ethyl(or butyl)-heterocyclic compounds and their pharmaceutically acceptable acid addition salts are neuroleptic agents. They are useful in the treatment of psychotic disorders.

  芳基哌嗪基乙基（或丁基）杂环化合物及其药用可接受的酸盐是神经阻滞剂。它们在治疗精神病性障碍方面很有用。
• Method of treating psychiatric conditions
  申请人：Pfizer Inc

  公开号：US06245766B1

  公开（公告）日：2001-06-12

  A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.

  一种用于治疗精神疾病或障碍的方法，所述精神疾病或障碍包括恐慌症、创伤后应激障碍和恐惧症等焦虑障碍，焦虑的精神病性发作，与精神病相关的焦虑，严重的重性抑郁障碍等精神情绪障碍，以及急性躁狂或与双相情感障碍相关的抑郁等精神障碍，如双相情感障碍、精神发育迟滞的行为表现、行为障碍或自闭症障碍、阿尔茨海默病型痴呆症和药物诱导的运动障碍以及基于神经退行性的运动障碍等运动障碍，包括人类在内的哺乳动物，包括向所述哺乳动物投予上述化合物的药效有效量或其药学上可接受的酸盐加合物，其中n、X、Y和Ar如上所定义。
• METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY
  申请人：——

  公开号：US20020004504A1

  公开（公告）日：2002-01-10

  A method for treating glaucoma and ischemic retinopathy in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the formula 1 or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined in the specification.

  在哺乳动物中治疗青光眼和缺血性视网膜病的方法，包括向所述哺乳动物施用公式1的化合物或其药学上可接受的酸盐的治疗有效量，其中n、X、Y和Ar如规范中定义。
• Benzothiazine and benzothiazole compounds useful as analgesics
  申请人：Adir et Compagnie

  公开号：US05234924A1

  公开（公告）日：1993-08-10

  Compound of general formula (I): ##STR1## where R.sub.1, R.sub.2, R.sub.3, n and X are defined in the description. Medicinal products.

  通式（I）的化合物：##STR1## 其中R.sub.1、R.sub.2、R.sub.3、n和X在描述中有定义。药用产品。